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ABSTRACT Neutrophils, the most abundant leukocytes in human blood, are essential fighter immune cells against microbial infection. Based on 
the finding that neutrophils can either restrict or promote cancer progression, tumor-associated neutrophils (TAN) are classified into 
anti-tumor N1 and pro-tumor N2 subsets. One of the major mechanisms underlying the tumor-promoting function of N2-TANs is 
suppression of adaptive immune cells, in particular, cytotoxic T lymphocytes. Currently, no established methodologies are available 
that can unequivocally distinguish immunosuppressive TANs and granulocytic/polymorphonuclear myeloid-derived suppressor 
cells (G/PMN-MDSC). In view of the critical role of PMN-MDSCs in immune evasion and resistance to cancer immunotherapy, as 
established from data obtained with diverse cancer models, therapeutic strategies targeting these cells have been actively developed 
to enhance the efficacy of immunotherapy. Here, we have reviewed the available literature on strategies targeting PMN-MDSCs and 
summarized the findings into four categories: (1) depletion of existing PMN-MDSCs, (2) blockade of the development of PMN-
MDSCs, (3) blockade of PMN-MDSC recruitment, (4) inhibition of immunosuppressive function. Owing to their high mobility to 
inflamed organs and ability to trespass the blood-brain barrier, neutrophils are outstanding candidate carriers in nanoparticle-based 
therapies. Another attractive application of neutrophils in cancer therapy is the use of neutrophil membrane-derived nanovesicles as 
a surrogate of extracellular vesicles for more efficient and scalable drug delivery. In the second part of the review, we have highlighted 
recent advances in the field of neutrophil-based cancer drug delivery. Overall, we believe that neutrophil-based therapeutics are a 
rapidly growing area of cancer therapy with significant potential benefits.
KEYWORDS Tumor-associated neutrophil; polymorphonuclear myeloid-derived suppressor cell; immunosuppression; cancer immunotherapy; 
nanoparticle drug delivery
Introduction
Neutrophils are the most abundant population of white blood 
cells and often the first responders to the site of infection. 
Neutrophils are activated to kill bacterial pathogens via a vari-
ety of mechanisms, including phagocytosis, degranulation of 
antimicrobial factors, and release of neutrophil  extracellular 
traps (NETs)1-3. Neutrophil differentiation and phenotype 
are profoundly influenced in multiple ways by solid tumors. 
Considerable evidence obtained from  experimental tumor 
models and cancer patients supports morphological and 
functional heterogeneity of tumor-associated  neutrophils 
(TANs)4-9. In a dichotomy similar to M1/M2 macrophages, 
TANs have been classified as tumor-inhibitory N1 and 
tumor-promoting N2 based on their functional differences10. 
Characteristic nuclear morphologies are potentially asso-
ciated with N1-polarized and N2-polarized TANs. For 
instance, N1 neutrophils have hypersegmented nuclei whereas 
N2 neutrophils have banded or ring-like nuclei10. Recently, 
 lectin-type oxidized LDL receptor-1 (LOX1)11 and fatty acid 
transport protein 2 (FATP2)12 were identified as distinguish-
ing factors for the two populations of neutrophils in cancer 
patients,  representing a significant advance in the classifica-
tion of functionally distinct neutrophils based on molecular 
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 markers. Despite being a convenient model to describe TANs, 
N1/N2 classification is an oversimplification of neutrophil 
heterogeneity. Further molecular characterization of TANs 
based on single cell gene expression analysis is warranted to 
define the spectrum of neutrophil polarization within the 
tumor microenvironment.
The distinction between TANs and granulocytic/ 
polymorphonuclear myeloid-derived suppressor cells 
(G/PMN-MDSCs) is a controversial issue7. Both share a cel-
lular lineage origin and several morphological and phenotypic 
features, and currently, no surface markers are available that 
can be readily used for distinguishing the two cell types. By 
definition, the difference is that PMN-MDSCs potently sup-
press T cells whereas TANs may or may not possess immu-
nosuppressive activity13-15. Considering N1/N2 classification, 
PMN-MDSCs and N2 neutrophils appear equivalent or essen-
tially the same population. We believe that PMN-MDSC still 
presents a valid and helpful definition to describe a special-
ized neutrophil state that promotes tumor progression mainly 
through dampening adaptive  immunity. Therefore, in this 
review, we will refer to immunosuppressive neutrophils and 
PMN-MDSCs interchangeably to  indicate the population of 
TANs with immunosuppressive activity.
In view of the dominant negative regulatory role of PMN-
MDSCs in anti-tumor immunity in many experimental cancer 
models, significant research has focused on understanding and 
targeting this cell population as a means of sensitizing tumors 
to current immunotherapies. Meanwhile, a separate yet related 
line of research has exploited the strong chemotactic property 
of neutrophils to deliver tumor-killing drugs. In the current 
review, we focus on two aspects, specifically, immunosuppres-
sive neutrophil targeting and neutrophil-based drug delivery. 
For details on functions and mechanisms of TANs and PMN-
MDSCs, readers may refer to a number of recent outstanding 
reviews1,7,16,17.
Targeting of immunosuppressive 
neutrophils
Immunotherapy has revolutionized cancer treatment and 
become a new pillar of cancer therapy. Among the vari-
ous immunotherapy modalities developed to date, immune 
 checkpoint blockade (ICB) via antibodies targeting immune 
checkpoint molecules, such as cytotoxic T-lymphocyte-
associated antigen 4 (CTLA4) and programmed death 
1/programmed death ligand 1 (PD-1/PD-L1), has made the 
most significant impact18,19. However, the efficacy of immu-
notherapy is limited to a subset of patients and specific 
cancer types, mainly due to de novo or acquired resistance 
to immunotherapy20,21, and driven by tumor-intrinsic or 
tumor-extrinsic factors22,23. Among the resistance mecha-
nisms, the impact of tumor-infiltrating PMN-MDSCs is one 
of the central barriers that impairs cytotoxic T lymphocytes 
(CTL) activity within the tumor bed. Thus, strategies targeting 
PMN-MDSCs, in combination with immunotherapy, present 
a promising approach to overcome resistance to immunother-
apy. The currently available methods of PMN-MDSC targeting 
are  classified as: (1) depletion of existing PMN-MDSCs, (2) 
blockade of the development of PMN-MDSCs, (3)  blockade 
of PMN-MDSC recruitment, and (4) inhibition of immuno-
suppressive function.
Depletion of existing PMN-MDSCs
Chemotherapeutic drugs are reported to adversely affect 
MDSC viability. One of the typical side-effects of gemcitabine, 
a chemotherapeutic agent for many cancer types, including 
pancreatic cancer, is myelotoxicity. A study by Eriksson et al.24 
demonstrated that gemcitabine is capable of reducing circulat-
ing MDSC and TGFβ-1 levels and elevating the effector T cell: 
Treg ratio in human pancreatic adenocarcinoma. The group 
showed a significant decrease in granulocytic but not mono-
cytic MDSCs in the peripheral blood of patients with pancreatic 
 adenocarcinoma eight days after gemcitabine treatment, sup-
porting the utility of gemcitabine in depleting PMN-MDSCs 
and enhancing immunotherapy. Another chemotherapeutic 
agent, 5-fluorouracil (5FU), causes cell death by  preventing 
synthesis of DNA and RNA25. Vincent and co-workers showed 
that 5FU induced a decrease in the  number of MDSCs in 
the tumor microenvironment via triggering apoptosis and 
promoting IFN-γ production by tumor- infiltrated T cells to 
enhance antitumor immunity in a mouse EL4 cancer model26. 
Moreover, 5FU showed no preference for killing monocytic 
over granulocytic MDSCs and exerted no significant effects on 
T, natural killer, dendritic or B cells. Therefore, both gemcit-
abine and 5FU are considered promising agents to eliminate 
PMN-MDSCs in cancer patients. The antitumor effects of 
these drugs may be mediated, at least in part, by their selective 
toxicity against PMN-MDSCs [Figure 1A(1)].
Targeting of surface markers presents an attractive depletion 
approach. In mouse models, anti-Gr1 or anti-Ly6G antibody 
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is often used to deplete PMN-MDSCs. However, Gr1 or Ly6G 
(part of the Gr1 antigen) is absent in humans, restricting 
this approach to experimental models. In cancer patients, 
CD33+ is used in combination with other markers, such as 
HLA-DR− CD15+, to identify PMN-MDSCs. Therefore, anti-
bodies and their derivatives targeting CD33 are putative can-
didate agents for PMN-MDSC depletion. AMV564 is a novel 
CD33/CD3 tetravalent bispecific antibody currently in early 
phase clinical trials for relapsed or refractory acute myeloid 
leukemia (AML) (NCT03144245). Cheng and co-workers27 
reported that AMV564 treatment efficiently decreased the 
number of MDSCs and increased the CD4+ and CD8+ T cell 
numbers in primary bone marrow microenvironments from 
patients with myelodysplastic syndromes. The CD33-targeted 
antibody drug conjugate, gemtuzumab ozogamicin (GO), 
was reapproved in 2017 for treatment of AML28. To improve 
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Figure 1 Different strategies of targeting immunosuppressive neutrophils. (A) Depletion of existing PMN-MDSCs: (1) Chemotherapeutic 
drugs, gemcitabine and 5-fluorouracil (5FU), directly induce apoptosis; (2) The anti-CD33 antibody, AMV564, induces NK cell-mediated 
 antibody-dependent cellular cytotoxicity (ADCC); (3) LXRβ agonists activate ApoE and induce apoptosis. (B) Blockade of the development of 
PMN-MDSCs: (1) The differentiation process from myeloid progenitor cells in bone marrow to MDSCs is blocked by ATRA, IL-12, or anti-G-CSF 
antibody; (2) Ultra-low doses of paclitaxel induce differentiation of MDSCs into non-immunosuppressive dendritic cells; (3) CpG oligonucleotide 
induces MDSC to differentiate into non-immunosuppressive macrophages. (C) Blockade of PMN-MDSC recruitment: Delivery of PMN-MDSCs 
into the tumor microenvironment via chemotaxis is effectively blocked by CXCR2 inhibitors (such as SB225002 and SX-682), neutralizing anti-
body or peptide (pepducin), mCCR5-Ig or other agents. (D) Inhibition of PMN-MDSC immunosuppressive potential: (1) Immunosuppressive 
gene expression programs in PMN-MDSCs are blocked by PI3K inhibitors, RTK inhibitors, COX2 inhibitors, CpG-STAT3ASO, S100A8/A9 inhib-
itors, the PDE5 inhibitor sildenafil or long noncoding RNA Pvt1; (2) Immunosuppressive products from PMN-MDSCs, such as ROS, RNS and 
Arginase 1, are neutralized by nor-NOHA, uric acid, and bardoxolone methyl. The figure was generated with BioRender.com.
Cancer Biol Med Vol 17, No 1 February 2020 35
treatment options, it is important to determine whether 
agents, such as AMV564 and GO, demonstrate anti-MDSC 
activity in patients with solid tumors and show combinatorial 
synergy with immunotherapy [Figure 1A(2)].
Novel strategies to stimulate apoptosis of MDSCs are 
under development. For example, Tavazoie et al.29 showed 
that apolipoprotein E (ApoE), which is transcriptionally 
activated by liver X nuclear receptor (LXR), reduces the 
survival levels of both tumoral and circulating granulocytic 
and monocytic MDSCs by triggering apoptosis in mouse 
and human cancer models [Figure 1A(3)]. LXRβ agonists, 
such as GW3965 and RGX-104, induced depletion of immu-
nosuppressive MDSCs (both granulocytic and monocytic) 
and impairment of tumors. Through depletion of MDSCs, 
LXRβ agonists augmented the efficacy of anti-PD-1 immu-
notherapy in melanoma and lung cancer models. Currently, 
the efficacy of RGX-104 as monotherapy and in combina-
tion with ICB immunotherapeutics, such as Nivolumab or 
Ipilimumab, is being evaluated in a phase I clinical trial 
for patients with malignant solid tumors and lymphoma 
(NCT02922764).
Taken together, the literature suggests that PMN-MDSCs 
can be efficiently depleted using chemotherapeutic or biolog-
ical agents and targeted therapeutics. When combined with 
immunotherapeutic strategies, these treatments significantly 
enhance the effectiveness of immunotherapy and prolong sur-
vival of cancer patients.
Blockade of the development of PMN-MDSCs
An alternative strategy to reduce PMN-MDSC number is to 
redirect their developmental pathway, either by inhibiting the 
conversion of immature myeloid cells into PMN-MDSCs or 
inducing differentiation of PMN-MDSCs into other mature 
myeloid cells that possess limited immunosuppressive activ-
ity. PMN-MDSC formation is induced by tumor-derived 
cytokines, such as granulocyte macrophage-colony stimulat-
ing factor (GM-CSF), granulocyte colony stimulating factor 
(G-CSF), and vascular endothelial growth factor (VEGF)30. 
These cytokines are capable of promoting accumulation of 
MDSCs originating from bone marrow and blocking their dif-
ferentiation into mature myeloid cells, such as granulocytes, 
dendritic cells, and macrophages31,32. Thus, inhibition of these 
growth factors, their receptors or implicated downstream 
pathways may impair the PMN-MDSC population. For exam-
ple, reduction in the number and activity of PMN-MDSCs 
by all-trans retinoic acid (ATRA)33, IL-1234, and anti-G-CSF 
 antibody35 have been reported [Figure 1B(1)].
Theoretically, normalizing aberrant differentiation of 
MDSCs back into mature myeloid cells with diminished 
immunosuppressive and enhanced antitumor activities 
presents an ideal strategy with little anticipated toxicity. A 
number of studies support this possibility. Paclitaxel is a 
well-known chemotherapy drug for several cancer types. 
Interestingly, Michels et al.36 demonstrated that ultra-low 
doses of paclitaxel, which neither increased MDSC apoptosis 
nor blocked MDSC generation, could stimulate differentia-
tion of tumor-infiltrating MDSCs into mature dendritic cells 
in a TLR4-independent manner in a murine melanoma model 
[Figure 1B(2)]. Immunostimulatory CpG oligonucleotides 
delivered via intratumoral injection reduced the immunosup-
pressive activity of MDSCs in the tumor bed by stimulating 
their differentiation into macrophages with tumoricidal capa-
bility37 [Figure 1B(3)].
Overall, blockade of the PMN-MDSC development, either 
by blocking their generation or inducing differentiation into 
non-suppressive myeloid cells, is an efficient strategy to abol-
ish immunosuppression induced by PMN-MDSCs.
Blockade of PMN-MDSC recruitment
PMN-MDSCs are recruited via specific chemotactic path-
ways. Several chemokine signaling pathways are involved in 
PMN-MDSC recruitment to the tumor microenvironment. 
Inhibitors of chemokine receptors are therefore promising 
candidate agents that may aid in preventing PMN-MDSCs 
from entering the tumor bed and shaping the immunosup-
pressive microenvironment (Figure 1C). Earlier studies using 
CXCR2 inhibitors (SB225002 and SX-682), a neutralizing 
antibody and peptide (pepducin) confirmed CXCR2 signal-
ing as the central pathway for recruitment of PMN-MDSCs. 
Notably, CXCR2 blockade inhibited tumor progression in 
various tumor models38-41 and restored the sensitivity of 
highly refractory tumor models to immunotherapy41-43, a tes-
timony for a key role of PMN-MDSCs in immunosuppression 
and resistance to cancer immunotherapy. A fusion protein, 
mCCR5-Ig, was generated to hinder PMN-MDSC accumula-
tion via blocking CCR5 signaling in melanoma models44,45. In 
animal models of breast cancer metastasis, blocking the γδT 
cell/IL-17/neutrophil axis by neutralization of IL17 or G-CSF 
prevented neutrophil accumulation and downregulated 
the T cell-suppressive phenotype46. Ongoing clinical trials 
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are underway to determine whether blocking PMN-MDSC 
recruitment can effectively enhance cancer immunotherapy. 
For example, NCT03161431 is an ongoing phase I clinical trial 
evaluating a combination of the CXCR1/2 inhibitor, SX-682, 
and ICB antibody, pembrolizumab, in patients with metastatic 
melanoma. 
Based on the above findings, it is reasonable to suggest that 
blocking recruitment of PMN-MDSCs presents an effective 
prophylactic approach to inhibit the immunosuppressive 
activity of the tumor microenvironment, which may improve 
the efficacy of immunotherapy.
Inhibition of the immunosuppressive function 
of PMN-MDSCs
Downregulation of the immunosuppressive function of 
PMN-MDSCs can be achieved by either silencing the signal-
ing that controls immunosuppressive activity or diminishing 
immunosuppressive products secreted by PMN-MDSCs. Such 
treatments may help reprogram the tumor microenvironment 
to have less hostility toward CTLs and improve the chances of 
success of cancer immunotherapy.
Various strategies have been developed to dampen the immu-
nosuppressive activity of PMN-MDSCs [Figure 1D(1)]. Patnaik 
et al.47 observed that inhibiting receptor tyrosine kinase signa-
ling with Cabozantinib in pten-/- p53-/- mouse prostate tumor 
models promoted infiltration of neutrophils with antitumor 
activities into tumors, attenuating cancer progression. In this 
context, CXCL12 and HMGB1 are two tumor-secreted neutro-
phil chemotactic factors that recruit CXCR4-expressing neutro-
phils with antitumor properties. Another study by our group 
demonstrated that other than recruiting N1-like neutrophils, 
cabozantinib as well as the dual PI3K/mTOR inhibitor, dac-
tolisib, significantly downregulated immunosuppressive genes, 
such as Arg1, Ncf1 and Ncf4, in tumor-infiltrating PMN-MDSCs 
through targeting PI3K signaling43. By suppressing PMN-
MDSCs, these drugs synergized with ICB to eradicate both 
primary and metastatic prostate tumors in the PB-Cre+ PtenL/L 
p53L/L Smad4L/L mouse model43. Isoform-selective PI3K inhib-
itors, such as the PI3Kγ inhibitor PI-54948,49, PI3Kβ inhibitor 
GSK263677150, PI3Kδ/γ inhibitor IPI-14551 and (-)-4-O-(4-O-
β-D-glucopyranosylcaffeoyl) quinic acid52 were shown to sup-
press tumor-promoting myeloid cells, including PMN-MDSCs, 
and enhance immunotherapy. Given the importance of STAT3 
in MDSC expansion and activation32, silencing of STAT3 in 
PMN-MDSCs via an antisense oligonucleotide tethered to CpG 
oligonucleotide (CpG-STAT3ASO) reduced circulating PMN-
MDSCs and promoted the CTL to Treg ratio in prostate can-
cer models53. Tumor-derived COX2-PGE2 signaling plays a key 
role in promotion of PMN-MDSCs in both animal models and 
human PBMCs, and COX2 inhibitors, such as celecoxib and 
SC-236, have been shown to diminish the number and activ-
ity of PMN-MDSCs, in part, through inhibition of STAT3 in 
myeloid cells54-60. S100A8/A9 is a heterodimeric pro-inflamma-
tory mediator involved in both chronic and acute inflammation 
through activation of TLR4- or RAGE-mediated inflammatory 
pathways61. In gastric cancer patients, PMN-MDSCs accumu-
lating in the tumor bed secreted higher levels of S100A8/A9. 
Inhibition of S100A8/A9 and its receptor (RAGE) impaired 
the ability of PMN-MDSCs to suppress T cell proliferation 
and IFN-γ production62. The effects of S100A8/A9 on blood, 
splenic and tumoral MDSCs were also effectively abolished by 
a peptide-Fc fusion protein (peptibody), which outperformed 
anti-Gr1 antibody and completely depleted both granulocytic 
and monocytic MDSCs in lymphoid organs and tumors in 
mice without affecting pro-inflammatory immune cell types, 
such as dendritic cells63. Inhibition of phosphodiesterase-5 
(PDE5) by sildenafil (Viagra, used to treat erectile dysfunction) 
induced downregulation of arginase 1 and nitric oxide syn-
thase-2, thereby reducing activity of intratumoral MDSCs64,65. 
Surprisingly, a long noncoding RNA, Pvt1, was shown to reg-
ulate the immunosuppressive activity of PMN-MDSCs in the 
tumor microenvironment, and siRNA-mediated silencing of 
Pvt1 inhibited intratumoral PMN-MDSC activity in the Lewis 
lung carcinoma mouse model66 [Figure 1D(1)].
The anti-inflammatory factors (enzymes, cytokines, and 
reactive chemicals) produced by PMN-MDSCs additionally 
present promising targets. Treatments that act by inhibiting 
these factors are considered the last line of defense against the 
effects of PMN-MDSCs [Figure 1D(2)]. Reactive oxygen spe-
cies (ROS) and reactive nitrogen species (RNS) are the main 
weapons used by PMN-MDSCs to cause tolerance or death 
of CTLs67-71 and tumorigenic mutations in epithelial cells72. 
Another major mechanism used by PMN-MDSCs to suppress 
T cells is production of Arginase-1 that leads to diminished 
L-arginine levels, affecting T cell function73,74. Arginase-1 
remains in the inactive form within granules of neutrophils 
and becomes activated when neutrophils release their granule 
content75,76. The agents shown to neutralize or inhibit the pro-
duction of these molecules include N-hydroxy-nor-l-arginine 
(nor-NOHA)67, uric acid70,77, and bardoxolone methyl78. 
A recent study by our group demonstrated that RNS from 
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intratumoral PMN-MDSCs promoted nitration of Tyr394 of 
lymphocyte-specific protein tyrosine kinase (LCK) in CTLs 
and abolished T cell receptor signaling through disruption 
of the phosphorylation cascade77. Neutralizing RNS with 
uric acid was a satisfactory strategy that negated the effects of 
PMN-MDSCs and greatly promoted the efficacy of immuno-
therapy in both prostate and lung cancer models. However, the 
optimal approach to neutralize PMN-MDSC-derived RNS in 
cancer patients remains to be established.
A particularly interesting strategy to target N2 neutrophils is 
through blocking neutrophil extracellular traps (NET). NETs 
are composed of DNA fibers with granule-derived antimicro-
bial proteins (such as neutrophil elastase, cathepsin G, and 
MMP-9) secreted by neutrophils through a process known 
as NETosis8. NETs can immobilize and neutralize pathogens 
including fungi, bacteria, and viruses79. Recently, NETs have 
been shown to assist metastasis by trapping circulating tumor 
cells (CTCs), promoting cancer cell invasion, and awakening 
cancer cells from dormancy80-83. Strategies to inhibit NETosis 
or remove existing NETs could therefore present an effective 
way to diminish metastasis. The agents exerting anti-NETosis 
effects in cancer models include DNase I-coated nanoparticles 
that digest NETs80, antibodies against NET-remodeled 
laminin81, heparin that sequesters histone from NETs with its 
negative charges83,84, and inhibitors of protein-arginine deimi-
nase 4 (PAD4), an enzyme required for NET formation85. Use 
of these inhibitors should be carefully evaluated in patients, 
since inhibition of NETs may also compromise their impor-
tant functions in innate immunity.
Challenges in selective targeting of 
immunosuppressive neutrophils
We have summarized the four main strategies employed to tar-
get PMN-MDSCs, including depletion using apoptosis-induced 
agents, blockade of the development, blockade of recruitment 
from the bone marrow, and elimination of immunosuppressive 
signaling and associated factors. Several important  challenges 
and issues remain in developing selective therapeutics to target 
this population of neutrophils. First, the methodology used to 
define PMN-MDSCs in experimental models and clinical sam-
ples makes evaluation cumbersome. Due to the lack of defin-
itive markers to distinguish PMN-MDSCs from other types 
of neutrophils, isolated intratumoral PMN-MDSCs must be 
subjected to a T cell co-culture assay to evaluate whether the 
therapeutic agent can diminish immunosuppressive activity. 
This method is feasible for experimental models but difficult to 
implement in clinical trials. Second, the signaling mechanisms 
used by PMN-MDSCs to suppress T cells are often hyperac-
tive in other cancer cells or M2-polarized macrophages in the 
tumor microenvironment. Therefore, it is often difficult to 
attribute the therapeutic effect solely to PMN-MDSCs. Third, 
due to the complexity and redundancy of immunosuppressive 
mechanisms, blocking one mechanism may be compensated by 
other mechanisms, leaving T cells still suppressed. Therefore, 
blockage of PMN-MDSC recruitment may be a favorable 
strategy because without continuous recruitment from the 
bone marrow, tumors are expected to exhaust their supply of 
infiltrating PMN-MDSCs rapidly and become susceptible to 
killing by CTLs activated by immunotherapy. Fourth, most of 
the existing knowledge on PMN-MDSCs has been obtained 
from mouse models. However, the differences between human 
and mouse immune systems, especially in the context of neu-
trophils, and their roles in cancer and immunotherapy make 
translation of findings from mouse models to clinical therapy 
a long and difficult process. To address these challenges, future 
research should focus on identifying biomarkers highly specific 
for PMN-MDSCs and developing more selective therapeu-
tics (antibody-drug conjugate or bispecific antibody based on 
highly selective PMN-MDSC surface markers). New human-
ized mouse models incorporating PMN-MDSCs, autologous 
cancer cells and T cells of human origin should be developed as 
a tool for elucidation of PMN-MDSC biology and therapeutics.
Neutrophil-based drug delivery
As the most abundant immune cells in the circulation, neu-
trophils play an essential role in immune responses to tissue 
damage or infection. Upon inflammation, neutrophils are 
the first immunocytes recruited to the inflammation site3. 
Owing to high responsiveness and mobility, neutrophils 
present an outstanding candidate cellular carrier for various 
antitumor reagents86. So far, two main strategies have been 
employed: (1) use of live neutrophils and (2) use of neutrophil 
 membrane-derived nanovesicles as drug delivery tools.
Neutrophils as a drug delivery carrier 
Targeting of solid tumors with nanoparticles (NPs) loaded with 
antitumor drugs is an attractive therapeutic option. However, 
the vast majority of administered NPs are not effectively deliv-
ered to solid tumors87. Limited NP-based delivery strategies 
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have been successful in the clinic and solving the NP delivery 
problem should accelerate clinical translation of nanomedi-
cine. The remarkable ability of neutrophils to migrate from the 
circulation to various tissues supports their utility as promising 
drug carriers to enhance the therapeutic effect88-91. Recently, 
Wang et al.92 showed that activated but not resting neutrophils 
or monocytes were able to take up drug-loaded albumin NPs 
in a Fcγ receptor-dependent manner. Neutrophils treated with 
albumin NPs loaded with Syk inhibitor, piceatannol, lost “out-
side-in” β2 integrin signaling activity and detached from the 
inflamed vasculature in vascular inflammation and lung injury 
models. This capability of activated neutrophils to take up NPs 
is potentially exploitable for cancer treatment.
In two studies, Chu et al.93,94 demonstrated that neutro-
phil-mediated delivery of NPs across the blood vessel barrier 
into tumor tissues after induction of inflammation is a valid 
approach to precisely deliver therapeutic agents in tumor 
models. In both investigations, acute stimulation of inflam-
mation, either via a monoclonal antibody or photosensitiza-
tion, was required for neutrophil recruitment. Neutrophils 
delivered pyropheophorbide-a loaded NPs or anti-CD11b 
antibody-linked gold nanorods to the tumor bed and induced 
a tumoricidal effect (Figure 2A).
A particular advantage of using neutrophils as the vehicle 
for drug delivery is their ability to penetrate the blood brain 
barrier (BBB) and reach inflamed brain tumors owing to high 
migratory capacity95,96. Xue et al.97 reported that neutrophils 
carrying paclitaxel (PTX) liposomes could penetrate the brain 
and suppress recurrence of glioma in mice whose tumors had 
been resected surgically. The pro-inflammatory factors gen-
erated at the site of resection triggered massive infiltration of 
neutrophils. The high concentration of inflammatory signals 
in the brain further triggered release of liposomal PTX from 
neutrophils, facilitating delivery of PTX to residual tumor 
cells (Figure 2A). As a result, neutrophil-mediated delivery of 
drugs efficiently impeded relapse and improved survival.
In contrast to the delivery of non-toxic agents, such as 
 photosensitizers or gold NPs in an in situ setting, loading neu-
trophils with toxic anti-cancer drugs ex vivo, such as paclitaxel, 
is expected to be a significant challenge, since neutrophils are 
highly sensitive and have a short lifetime ex vivo. Moreover, 
chemotherapeutic drugs may significantly impair neutrophil 
viability and functions, such as cell migration98. Nevertheless, 
Xue and colleagues97 showed that PTX liposomes exert negli-
gible toxicity to neutrophils compared with free PTX, suggest-
ing that ex vivo loading of neutrophils with carefully designed 
chemotherapeutic drug-containing NPs is  feasible and loaded 
neutrophils may survive long enough after infusion to effec-
tively target tumors and generate the desired therapeutic effect.
While still an emerging field of research, studies to date 
have revealed that the use of neutrophils as vesicles for drug 
delivery can improve the efficacy of immunotherapy and 
aid in resistance to tumor recurrence. With broader appli-
cation of immunotherapy in cancer treatment, we expect 
 neutrophil-mediated drug delivery to become a valuable 
complementary approach.
Neutrophil membrane-derived nanovesicles 
for drug delivery
Lipid-based nanomaterials, such as liposomes, are extensively 
used as carriers for drug delivery due to several suitable phys-
ical and chemical properties. However, the exogenous nature 
of liposomes may elicit immunogenicity in vivo, leading to 
compromised therapeutic effects and elevated risk of systemic 
immune responses99,100.
Extracellular vesicles (EV) are lipid bilayer-delimited 
 particles naturally released from cells that are loaded with pro-
teins, lipids, nucleic acids and sometimes even organelles. These 
vesicles play important roles in intercellular  communication 
under both physiological and pathological conditions. A vari-
ety of cell adhesion molecules are expressed on the EV surface, 
facilitating their utility as carriers for drug delivery101. However, 
clinical application of EVs is currently impeded by low yield, 
inefficient drug loading and difficulty in scalability102.
Gao et al.102 reported a strategy to generate EVs using nitro-
gen cavitation (NC-EVs) that instantly disrupts neutrophils 
to form nanosized membrane vesicles. NC-EVs are similar to 
naturally secreted EVs (NS-EVs) by neutrophils but include 
less nuclear acids and organelles. Due to the high yield of 
production (16 times higher than NS-EVs), NC-EVs are 
potentially applicable for clinical use. In the study, NC-EVs 
loaded with piceatannol (an anti-inflammatory drug) alle-
viated acute lung inflammation/injury and sepsis induced 
by lipopolysaccharide in mice (Figure 2B). The data suggest 
that nitrogen cavitation is feasible for efficient manufacture 
of neutrophil- membrane-derived EVs on a large scale. This 
approach may therefore be adapted for the efficient produc-
tion of  chemotherapy  drug-loaded NC-EVs.
A nanosized neutrophil-mimicking drug delivery system 
(NM-NP) was developed by Kang and co-workers by coating 
neutrophil membranes on the surface of poly (lactic-co-glycolic 
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acid) NPs without damaging membrane-associated proteins 
and binding affinities103. Compared with uncoated NPs, 
NM-NPs displayed enhanced cellular association under shear 
flow in vitro and higher capture efficiency of CTCs in vivo. 
For therapeutic purposes, NM-NPs loaded with carfilzomib, a 
second-generation proteasome inhibitor, exhibited impressive 
activity in depleting CTCs in the circulation and inhibiting the 
initiation and development of metastasis in animal  models 
(Figure 2B). This exciting study reveals the potential of of 
NP-loaded neutrophil-derived vesicles in  treating metastasis, 
a direction warranting further investigation.
Conclusions and perspectives
We have reviewed two related topics: (1) how to target immu-
nosuppressive neutrophils and (2) how to use neutrophils 
to battle cancer. For targeting immunosuppressive neutro-
phils, four types of strategies have been developed, including 
depletion, redirection of differentiation, blockage of recruit-
ment, and functional inactivation of PMN-MDSCs. These 
approaches require a deeper mechanistic understanding of 
neutrophils in cancer development and immune evasion. 
Among the many challenges of neutrophil targeting, perhaps 
the most prominent is molecular discrimination of TANs, 
especially PMN-MDSCs, from the remaining neutrophil pop-
ulations required for innate immunity against bacterial and 
fungal pathogens. We believe that technological advances, 
especially single cell profiling techniques, such as single 
cell RNA-seq and singe cell proteomics, will lead to greatly 
enhanced abilities to classify heterogeneous neutrophil popu-
lations, pinpoint specific  protein markers in “bad” neutrophils 
and spare “good”  neutrophils to avoid neutropenia as a major 
side-effect of neutrophil-targeted therapy.
Neutrophils are a double-edged sword in cancer devel-
opment. Strategies should be developed not only to  disrupt 
pro-tumor neutrophils but also reinstate anti-tumor 
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Figure 2 Neutrophil-based drug delivery. The inflammatory tumor microenvironment exacerbated by tumor-recognizing therapeutic anti-
bodies, photosensitization or surgery enhances the recruitment of drug/NP-loaded neutrophils or neutrophil membrane-derived nanovesicles, 
which is the most essential prerequisite for neutrophil-based drug delivery. (A) NP-loaded neutrophils. Neutrophils carry therapeutic lipos-
omes (loaded ex vivo, details not shown), albumins or CD11b antibody-coated NPs (engulfed by circulating neutrophils) and travel into the 
tumor microenvironment to deliver the drugs following chemoattraction by tumor-emitted pro-inflammatory signals. The neutrophils penetrate 
the blood brain barrier (BBB) to exert their effects. (B) Neutrophil membrane-derived nanovesicles. Nanovesicles generated using neutrophil 
 membranes are loaded with drugs (such as piceatannol) or form neutrophil-mimicking NPs (NM-NPs). The neutrophil-derived properties of 
nanovesicles allow homing to the tumor microenvironment for therapeutic delivery. The figure was generated with BioRender.com.
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neutrophils. Application of neutrophils and their membranes 
for better drug delivery and novel therapeutics has already 
generated impressive results in preclinical models and neu-
trophil-based therapeutics present a rapidly growing area of 
cancer therapy. With the accumulating research efforts dedi-
cated to targeting tumor-associated immunosuppressive neu-
trophils and devising novel neutrophil-based therapies, we 
expect significantly higher numbers of cancer patients to ben-
efit from immunotherapy and personalized targeted therapies 
in the next decade.
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